U.S. may expand Nvidia and AMD’s 15% China chips deal to other companies
COLUMBUS, OH – Bath & Body Works, Inc. (NYSE:BBWI) has announced that its CEO, Gina Boswell, will be taking a temporary medical leave starting Thursday to undergo scheduled surgery. The company disclosed this development in a Form 8-K filed with the U.S. Securities and Exchange Commission today.
The CEO’s absence is expected to last several weeks, according to the statement. The company has attached a message from Boswell to its associates as part of the filing, which details her temporary departure. The specifics of the company’s interim leadership structure during Boswell’s absence were not provided in the filing.
Bath & Body Works, a major retail store chain known for its personal care and fragrance products, operates under the legal name Bath & Body Works, Inc. and is incorporated in Delaware. The company’s headquarters are in Columbus (WA:CLC), Ohio, and it is listed on the New York Stock Exchange under the ticker symbol BBWI.
The 8-K filing also contains customary forward-looking statements, cautioning that actual results could significantly differ from those anticipated due to various risks and uncertainties. These include factors beyond the company’s control and those periodically reported in filings with the SEC.
The company has not provided any further details on the expected impact of the CEO’s absence on operations or financial performance. The filing reiterates the company’s policy not to update forward-looking statements to reflect events or circumstances after the report date unless required by law.
This news comes directly from the latest SEC filing and reflects the company’s current reported events without speculation or analysis of potential outcomes. Bath & Body Works has not commented beyond the information provided in the SEC filing.
In other recent news, Bath & Body Works reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $2.09, exceeding the forecasted $2.04. However, the company experienced a 4% year-over-year decline in net sales, reaching $2.8 billion. Despite the earnings beat, the company’s stock faced a decline amid concerns about future growth prospects. Bath & Body Works has reaffirmed its financial guidance for the first quarter and full fiscal year 2025, projecting net sales growth between 1% and 3% and earnings per diluted share ranging from $3.25 to $3.60. The company aims to maintain transparency and trust with its stakeholders by upholding its previously stated financial targets. TD Cowen’s Oliver Chen identified Bath & Body Works as a defensive stock pick, maintaining a buy rating despite recent market challenges. The company continues to focus on product innovation and expanding its store presence, including international sales, to drive growth. Bath & Body Works’ strategic initiatives include launching new product lines and expanding its loyalty program to enhance consumer engagement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.